Korsana Biosciences, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses: | ||||
| Research and development (1) | $42,139 | $20,479 | $69,130 | $20,732 |
| General and administrative (2) | 6,135 | 1,478 | 12,355 | 1,590 |
| Total operating expenses | 48,274 | 21,957 | 81,485 | 22,322 |
| Loss from operations | (48,274) | (21,957) | (81,485) | (22,322) |
| Other income: | ||||
| Interest income | 1,849 | 234 | 4,190 | 374 |
| Total other income | 1,849 | 234 | 4,190 | 374 |
| Net loss and comprehensive loss | $(46,425) | $(21,723) | $(77,295) | $(21,948) |
| Net loss per share attributable to common stockholders, basic and diluted | $(3.19) | $(39.49) | $(13.42) | $(47.67) |
| Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | $(3,190.41) | $ - | $(13,416.90) | $ - |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 13,525,610 | 550,061 | 5,412,840 | 460,382 |
| Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | 1,026 | - | 348 | - |
(1)
Includes related party amount of $23,662 and $39,849 for thethree and nine months ended September 30, 2026, respectively, and $20,262 and $20,298 for thethree and nine months ended September 30, 2025, respectively (see Note 9).
(2)
Includes related party amount of $0 for thethree and nine months ended September 30, 2026, and $721 for thethree and nine months ended September 30, 2025 (see Note 9).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.